Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

This study has been completed.
Information provided by (Responsible Party):
Janssen Research & Development, LLC Identifier:
First received: June 7, 2011
Last updated: July 1, 2015
Last verified: July 2015
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).

Condition Intervention Phase
Crohn's Disease
Inflammatory Bowel Disease
Drug: Group 2 ustekinumab 130 mg
Drug: Group 3: ustekinumab approximately 6 mg/kg
Drug: Group 1: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)

Resource links provided by NLM:

Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Clinical Response [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
    The number of patients in clinical response, as measured by the reduction from baseline in the Crohn's Disease Activity Index (CDAI), which is assessed by collecting information on extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being.

Secondary Outcome Measures:
  • Clinical remission [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    The number of patients in clinical remission, as assessed by the CDAI.

  • Clinical improvement/response [ Time Frame: Study visits through Week 8 ] [ Designated as safety issue: No ]
    The number of patients experiencing clinical response or improvement, as measured by the reduction from baseline in CDAI score.

Enrollment: 769
Study Start Date: July 2011
Study Completion Date: July 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 001
Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
Drug: Group 1: Placebo
Form=solution for injection, route=intravenous use, in a single dose.
Experimental: 002
Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
Drug: Group 2 ustekinumab 130 mg
Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Experimental: 003
Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
Drug: Group 3: ustekinumab approximately 6 mg/kg
Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

Detailed Description:
This study (CNTO1275CRD3001 or "UNITI-1") examines ustekinumab (an antibody medication that inhibits the inflammatory proteins IL-12 and IL-23) versus a placebo (otherwise identical except without the ustekinumab antibody) given intravenously (by an IV) in adults with moderately to severely active Crohn's disease who previously did not respond to, lost response to, or could not tolerate TNF-antagonist medications (specifically, infliximab, adalimumab or certolizumab pegol). Ustekinumab (also known as Stelara) is approved as a treatment for the skin condition of moderate to severe plaque-type psoriasis, but this study will examine if ustekinumab can provide benefit in Crohn's disease and also assess for any risks or side effects. Both the positive and negative outcomes of IV placebo versus two different doses of IV ustekinumab will be tracked and compared over eight weeks, in approximately 703 patients. Patients enrolling in this study will be assigned to one of the 3 treatment groups by chance (randomly, like rolling dice), and all will receive a single IV administration of study agent at the first study visit (after the screening period), and then will be asked to return for 3 additional visits through Week 8. Patients who complete this study through the Week 8 visit and remain eligible can enter the maintenance study (CNTO1275CRD3003 or "IM-UNITI"), where they will receive additional study agent, including the administration of ustekinumab in patients who receive placebo in this study and have not had improvement in their Crohn's disease. Patients who do not enter the CNTO1275CRD3003 study will have a final safety follow-up visit approximately 20 weeks after they received study agent when they entered into this study at the Week 0 visit. .All patients will receive a single intravenous (IV) administration of study drug (either placebo or ustekinumab) at the first (week 0) visit when they enter the study.There are 3 treatment groups: Group 1: Placebo; Group 2: ustekinumab 130 mg, Group 3: weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy
  • Have active Crohn's disease, defined as a baseline Crohn's Disease Activity Index (CDAI) score of >= 220 and <= 450
  • Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the treatment of Crohn disease and did not respond initially (ie, primary nonresponse)
  • Or responded initially but then lost response with continued therapy (ie, secondary nonresponse)
  • Or were intolerant to the medication
  • Have screening laboratory test results within protocol-specified parameters.

Exclusion Criteria:

  • Patients who have had any kind of bowel resection within 6 months
  • Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent
  • Patients who have received infliximab, adalimumab or certolizumab pegol < = 8 weeks before the first administration of study drug
  • Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
  • Patients with a history of or ongoing chronic or recurrent infectious disease
  • Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01369329

  Hide Study Locations
United States, Arizona
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
La Jolla, California, United States
Los Angeles, California, United States
Redwood City, California, United States
San Carlos, California, United States
San Diego, California, United States
United States, Colorado
Lone Tree, Colorado, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, Florida
Gainesville, Florida, United States
Jacksonville, Florida, United States
Weston, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Decatur, Georgia, United States
Macon, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Evanston, Illinois, United States
United States, Iowa
Clive, Iowa, United States
United States, Kentucky
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Baton Rouge, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
Chevy Chase, Maryland, United States
Towson, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Chesterfield, Michigan, United States
Novi, Michigan, United States
Troy, Michigan, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Mississippi
Ocean Springs, Mississippi, United States
United States, Missouri
Lees Summit, Missouri, United States
Mexico, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
Marlton, New Jersey, United States
Morristown, New Jersey, United States
United States, New York
Great Neck, New York, United States
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
United States, Ohio
Beavercreek, Ohio, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Bend, Oregon, United States
Springfield, Oregon, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, South Carolina
North Charleston, South Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Houston, Texas, United States
Tyler, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Charlottesville, Virginia, United States
Chesapeake, Virginia, United States
Norfolk, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Bedford Park, Australia
Box Hill, Australia
Central Queensland M C, Australia
Concord, Australia
Garran, Australia
Liverpool, Australia
Malvern, Australia
Parkville, Australia
Innsbruck, Austria
St Poelten, Austria
Wien, Austria
Brussel, Belgium
Leuven, Belgium
Liege, Belgium
Rio De Janeiro, Brazil
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Brandon, Manitoba, Canada
Winnipeg, Manitoba, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Czech Republic
Hradec Kralove, Czech Republic
Usti Nad Labem, Czech Republic
Herlev, Denmark
Silkeborg, Denmark
Amiens Cedex 1, France
Caen, France
Lille, France
Marseille, France
Nantes Cedex 1, France
Paris Cedex 18, France
Paris, France
Pessac, France
Reims, France
Rouen, France
Toulouse, France
Berlin, Germany
Erlangen, Germany
Essen, Germany
Frankfurt, Germany
Freiburg, Germany
Halle, Germany
Hamburg, Germany
Hannover, Germany
Heidelberg, Germany
Jena, Germany
Kiel, Germany
Lÿneburg, Germany
Mannheim, Germany
Minden, Germany
München, Germany
Münster, Germany
Regensburg, Germany
Tübingen, Germany
Ulm, Germany
Szekszard, Hungary
Akureyri, Iceland
Reykjavik, Iceland
Dublin 9, Ireland
Dublin, Ireland
Jerusalem, Israel
Tel Hashomer, Israel
Chikushino, Japan
Fukuoka, Japan
Hamamatsu, Japan
Kagoshima, Japan
Nishinomiya, Japan
Ohtsu, Japan
Oita, Japan
Osaka, Japan
Sakura, Japan
Sapporo, Japan
Tokyo, Japan
Yokkaichi, Japan
Korea, Republic of
Seoul, Korea, Republic of
Amsterdam, Netherlands
Maastricht, Netherlands
Rotterdam, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Grafton, New Zealand
Hamilton, New Zealand
Krakow, Poland
Lodz, Poland
Belgrade, Serbia
Nis, Serbia
South Africa
Cape Town, South Africa
Overport, South Africa
Madrid, Spain
Sagunto, Spain
United Kingdom
Birmingham, United Kingdom
Brighton, United Kingdom
Bristol, United Kingdom
Cambridge, United Kingdom
Cardiff, United Kingdom
Exeter, United Kingdom
Gloucester, United Kingdom
Harrow, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Norwich, United Kingdom
Nottinghamshirecc, United Kingdom
Oxford, United Kingdom
Shropshire, United Kingdom
South Shields, United Kingdom
Southampton, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Responsible Party: Janssen Research & Development, LLC Identifier: NCT01369329     History of Changes
Other Study ID Numbers: CR018415  CNTO1275CRD3001  2010-022758-18 
Study First Received: June 7, 2011
Last Updated: July 1, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Janssen Research & Development, LLC:
moderately to severely active Crohn's Disease
tumor necrosis factor, Stelara

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Pharmaceutical Solutions
Dermatologic Agents processed this record on December 05, 2016